阿片类药物使用障碍药物市场－全球产业规模、份额、趋势、机会和预测，按药物类型、给药途径、配销通路、地区和竞争情况细分，2020 年至 2030 年

2024 年全球鸦片类药物使用障碍药物市场价值为 38.7 亿美元，预计到 2030 年将达到 65.9 亿美元，复合年增长率为 9.26%。全球阿片类药物使用障碍药物市场是更广泛的製药业中一个充满活力且关键的领域，致力于解决全球日益严重的鸦片类药物成瘾危机。随着阿片类药物滥用和过量使用相关死亡人数达到令人震惊的水平，该市场在提供有效解决方案以应对这一公共卫生危机方面发挥关键作用。阿片类药物使用疾患 (OUD) 药物涵盖一系列旨在治疗鸦片类药物成瘾的药物干预措施，包括处方止痛药和海洛因等非法物质。这些药物通常分为三类：鸦片激动剂、部分激动剂和拮抗剂，每种药物都有其独特的作用机转。该市场的主要药物包括美沙酮、丁丙诺啡、纳曲酮和纳洛酮，其给药形式多种多样，例如口服片剂、舌下膜剂或註射剂。

关键市场驱动因素

不断升级的鸦片危机

主要市场挑战

监理复杂性

主要市场趋势

扩大药物辅助治疗（MAT）

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球阿片类药物使用疾患药物市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依药物类型（激动剂药物、拮抗剂药物、其他）
  • 依给药途径（口服、肠胃外、舌下、鼻腔）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按公司分类（2024）
  • 按地区
• 市场地图

第六章：北美阿片类药物使用疾患药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲阿片类药物使用疾患药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太阿片类药物使用障碍药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美洲阿片类药物使用障碍药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲阿片类药物使用疾患药物市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章： 大环境分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Mallinckrodt Pharmaceuticals
• Hikma Pharmaceuticals Inc
• Collegium Pharmaceutical, Inc.
• Braeburn, Inc.
• Purdue Pharma LP
• Curia Global Inc.
• EMERGENT
• Bristol-Myers Squibb, Srl
• Alkermes, Inc.
• Indivior Inc.

第 16 章：策略建议

第17章调查会社について・免责事项

Global Opioid Use Disorder Drugs Market was valued at USD 3.87 Billion in 2024 and is expected to reach USD 6.59 Billion in the forecast period with a CAGR of 9.26% through 2030. The Global Opioid Use Disorder Drugs Market is a dynamic and critical segment within the broader pharmaceutical industry, dedicated to addressing the escalating crisis of opioid addiction worldwide. With opioid abuse and overdose-related deaths reaching alarming levels, this market plays a pivotal role in providing effective solutions to combat this public health crisis. Opioid Use Disorder (OUD) drugs encompass a range of pharmaceutical interventions designed to treat addiction to opioids, including prescription painkillers and illicit substances like heroin. These medications typically fall into three categories: opioid agonists, partial agonists, and antagonists, each with its unique mechanism of action. Key drugs within this market include methadone, buprenorphine, naltrexone, and naloxone, which are administered in various forms such as oral tablets, sublingual films, or injectables.

Key Market Drivers

Escalating Opioid Epidemic

The escalating opioid epidemic has significantly influenced the Global Opioid Use Disorder (OUD) Drugs Market, reshaping the pharmaceutical landscape in response to this pressing public health crisis. This crisis, marked by the widespread misuse of prescription opioids and the proliferation of illicit substances like heroin, has led to devastating consequences, including a substantial number of opioid-related deaths. According to provisional data from the Centers for Disease Control and Prevention (CDC), there were an estimated 107,543 drug overdose deaths in the United States during 2023, with approximately 81,083 involving opioids. As communities confront the severe impacts of addiction, the demand for effective treatments has surged, creating opportunities for pharmaceutical companies to develop, market, and distribute a range of OUD drugs.

The opioid epidemic has unfolded on a global scale, transcending geographical and demographic boundaries. Governments, healthcare organizations, and the public have recognized the urgency of addressing this crisis comprehensively. This collective awareness has spurred significant investments in addiction treatment programs and policies aimed at expanding access to OUD drugs. However, challenges remain. In 2021, an estimated 2.5 million people aged 18 years or older in the U.S. had opioid use disorder, yet only 22% received medications to treat it. Addressing such gaps is crucial for mitigating the epidemic's impact. Furthermore, advancements like extended-release formulations have made treatment more convenient for patients, contributing to improved adherence and outcomes. As healthcare professionals and policymakers continue to grapple with the opioid crisis, the pharmaceutical industry remains pivotal in developing innovative medications to effectively treat OUD.

Key Market Challenges

Regulatory Complexity

One of the primary challenges is the lack of uniformity in regulations across different regions and countries. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and counterparts in other nations, have unique guidelines and requirements for OUD medications. This variation can lead to confusion and increased compliance costs for pharmaceutical companies operating internationally. The opioid epidemic is a rapidly evolving crisis, and regulatory agencies often struggle to keep pace with emerging trends and challenges. This lag in adapting regulations can hinder the timely approval of new medications and treatment modalities, impeding the market's ability to respond effectively to the crisis.

OUD medications, including opioid agonists like methadone and buprenorphine, are subject to strict regulations surrounding their prescription and dispensing. Healthcare providers must undergo specialized training and obtain waivers to prescribe these medications, creating barriers to access. Furthermore, stringent record-keeping requirements and oversight can deter providers from offering these treatments. Some OUD medications are subject to Risk Evaluation and Mitigation Strategies, which impose additional requirements on manufacturers and healthcare providers. While these strategies are intended to enhance the safe use of medications, they can also increase the administrative burden and costs associated with bringing OUD drugs to market.

Key Market Trends

Expansion of Medication-Assisted Treatment (MAT)

One of the most significant trends in the OUD Drugs Market is the increasing adoption of Medication-Assisted Treatment (MAT). MAT combines pharmacotherapy, such as opioid agonists (e.g., methadone and buprenorphine), with counseling and behavioral therapies to address opioid addiction comprehensively. MAT is now widely recognized as the gold standard of care for OUD, and its expansion has significantly boosted the market. Increased Access to Treatment: MAT programs have proliferated, making treatment more accessible to individuals grappling with OUD. The availability of MAT in a variety of healthcare settings, including specialized clinics, primary care offices, and even pharmacies, has broadened the reach of OUD treatment. MAT has demonstrated its effectiveness in reducing opioid misuse, promoting long-term recovery, and preventing opioid overdose deaths. As more individuals have access to MAT, better treatment outcomes become achievable, leading to increased confidence in these therapies.

Key Market Players

• Mallinckrodt Pharmaceuticals
• Hikma Pharmaceuticals Inc
• Collegium Pharmaceutical, Inc.
• Braeburn, Inc.
• Purdue Pharma L.P.
• Curia Global Inc.
• EMERGENT
• Bristol-Myers Squibb, S.r.l
• Alkermes, Inc.
• Indivior Inc.

Report Scope:

In this report, the Global Opioid Use Disorder Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Opioid Use Disorder Drugs Market, By Drug Type:

• Agonist Drugs
• Antagonist Drugs
• Others

Opioid Use Disorder Drugs Market, By Route of Administration:

• Oral
• Parenteral
• Sublingual
• Nasal

Opioid Use Disorder Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Opioid Use Disorder Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Opioid Use Disorder Drugs Market.

Available Customizations:

Global Opioid Use Disorder Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Opioid Use Disorder Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Agonist Drugs, Antagonist Drugs, Others)
  • 5.2.2. By Route of Administration (Oral, Parenteral, Sublingual, Nasal)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Opioid Use Disorder Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Opioid Use Disorder Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Opioid Use Disorder Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Opioid Use Disorder Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Opioid Use Disorder Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Opioid Use Disorder Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Opioid Use Disorder Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Opioid Use Disorder Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Opioid Use Disorder Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Opioid Use Disorder Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Opioid Use Disorder Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Opioid Use Disorder Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Opioid Use Disorder Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Opioid Use Disorder Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Opioid Use Disorder Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Opioid Use Disorder Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Distribution Channel

9. South America Opioid Use Disorder Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Opioid Use Disorder Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Opioid Use Disorder Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Opioid Use Disorder Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Opioid Use Disorder Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Opioid Use Disorder Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Opioid Use Disorder Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Opioid Use Disorder Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Mallinckrodt Pharmaceuticals
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Hikma Pharmaceuticals Inc
• 15.3. Collegium Pharmaceutical, Inc.
• 15.4. Braeburn, Inc.
• 15.5. Purdue Pharma L.P.
• 15.6. Curia Global Inc.
• 15.7. EMERGENT
• 15.8. Bristol-Myers Squibb, S.r.l
• 15.9. Alkermes, Inc.
• 15.10. Indivior Inc.

16. Strategic Recommendations

17. About Us & Disclaimer